Cent Eur J Public Health 2004, 12(Supplement):S54-S56

Amphotericin B, its Lipid Formulations and Conjugates with Polymers

Kubicová L.1, Pravda M.1, Buchta V.1, Vopršalová M.1, Sedlák M.2
1 Charles University in Prague, Faculty of Pharmacy in Hradec Králové
2 Department of Organic Chemistry, University of Pardubice, Czech Republic

The minireview is focused on novel findings concerning mechanism of action, lipid formulations, polymer conjugates, and structural modifications of amphotericin B.

Keywords: amphotericin B, fungi, systemic mycoses, liposome, lipid formulation, toxicity, prodrugs

Published: March 1, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kubicová L, Pravda M, Buchta V, Vopršalová M, Sedlák M. Amphotericin B, its Lipid Formulations and Conjugates with Polymers. Cent Eur J Public Health. 2004;12(Supplement):S54-56. PubMed PMID: 15141979.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zotchev SB: Polyene macrolide antibiotics and their applications in human therapy. Curr Med Chem 2003; 10: 211-223. Go to original source...
    2. Zhao X, Calderone RA: Antifungals currently used in the treatment of invasive fungal diseases. In: Calderone RA, Cihlar RL eds. Fungal Pathogenesis - Principles and Clinical Applications. New York, Marcel Dekker, 2002: 559-577. Go to original source...
    3. Gruszecki WI, Gagos M, Herec M: Dimers of polyene antibiotic amphotericin B detected by means of fluorescence spectroscopy: molecular organization in solution and in lipid membranes. J Photochem Photobiol B 2003; 69: 49-57. Go to original source...
    4. Milhaud J, Ponsinet V, Takashi M, Michels B: Interactions of the drug amphotericin B with phospholipid membranes containing or not ergosterol: new insight into the role of ergosterol. Biochim BiophysActa 2002; 1558: 95-108. Go to original source...
    5. Paquet M-J, Fournier I, Barwicz J, Pierre T, Auger M: The effects of amphotericin B on pure and ergosterol- or cholesterol-containing dipalmitoylphosphatidylcholine bilayers as viewed by 2 H NMR. Chem Phys Lipids 2002; 119: 1-11. Go to original source...
    6. Baginski A, Resat H, Borowski E: Comparative molecular-dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim Biophys Acta 2002; 1567: 63-78. Go to original source...
    7. Charbonneau C, Fournier I, Dufresne S, Barwicz J, Tancrede P: The interactions of amphotericin B with various sterols in relation to its possible use in anticancer therapy. Biophys Chem 2001; 91: 125-133. Go to original source...
    8. Harbarth S, Pestotnik SL, Lloyd JF, Burke JP, Samore MH: The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy. Am J Med 2001; 111: 528-534. Go to original source... Go to PubMed...
    9. Rogers PD, Pearson MM, Cleary JD, Sullivan DC, Chapman SW: Differential expression of genes encoding immunomodulatory proteins in response to amphotericin B in human mononuclear cells identified by cDNA microarray analysis. J Antimicrob Chemother 2002; 50: 811-817. Go to original source... Go to PubMed...
    10. Inselmann G, Inselmann U, Heidemann HT:Amphotericin B and liver function. Eur J Int Med 2002; 13: 288-292. Go to original source...
    11. Stuecklin-UtschA, Hasan C, Bode U, Fleischhack G: Pancreatic toxicity after liposomal amphotericin B. Mycoses 2002; 45: 170-173. Go to original source... Go to PubMed...
    12. Foote RH: Spermicidal effects of amphotericin B and nystatin on bull and rabbit sperm and contraceptive effects in rabbits. Contraception 2002; 66: 193-197. Go to original source... Go to PubMed...
    13. Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EGV, Hawkey PM, Herbrecht R, Marks DI, Moraleda JM, Park GR, Senn SJ, Viscoli C: A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Therap 2003; 25: 1295-1320. Go to original source...
    14. Wali RK, Henrich WL: Recent developments in toxic nephropathy. Curr Opin Nephrol Hypertens 2002; 11: 155-163. Go to original source...
    15. Arikan S, Rex JH: New agents for the treatment of systemic fungal infections - current status. Expert Opin Emerging Drugs 2002; 7: 3-32. Go to original source... Go to PubMed...
    16. Dupont B: Overview of the lipid formulations of amphotericin B. JAntimicrob Chemother 2002; 49, Suppl. S1: 31-36. Go to original source...
    17. Bau P, Bolard J, Dupouy-Camet J: Heated amphotericin to treat leishmaniasis. Lancet Infect Dis 188; 3: 2003. Go to original source...
    18. Rogers PD, Barker KS, Herring V, Jacob M: Heat-induced superaggregation of amphotericin B attenuates its ability to induce cytokine and chemokine production in the human monocytic cell line THP-1. J Antimicrob Chemother 2003; 51: 405-408. Go to original source... Go to PubMed...
    19. Kayser O, Olbrich C, Yardley V, KiderlenAF, Croft SL: Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm 2003; 254: 73-75. Go to original source... Go to PubMed...
    20. Adams ML, Andes DR, Kwon GS: Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. Biomacromolecules 2003; 4: 750-757. Go to original source... Go to PubMed...
    21. Mayer J, Doubek M, Doubek J, Horký D, Schee P, Štěpánek M: Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: Animal experiments and clinical study. J Infect Dis 2002; 186: 379-388. Go to original source... Go to PubMed...
    22. Vieira DB, Carmona-Ribeiro AM: Synthetic bilayer fragments for solubilization of amphotericin B. J Colloid Interface Sci 2001; 244: 427-431. Go to original source...
    23. Imhof A, Walter RB, Schaffner A: Continuous infusion of escalated doses of amphotericin B deoxycholate:An open-label observation study. Clin Infect Dis 2003; 36: 943-951. Go to original source... Go to PubMed...
    24. Greenwald RB: PEG drugs: an overview. J Controlled Release 2001; 74: 159-171. Go to original source... Go to PubMed...
    25. Greenwald RB, Choe YH, McGuire J, Conover ChD: Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev 2003; 55: 217-250. Go to original source... Go to PubMed...
    26. Sedlák M, Buchta V, Kubicová L, Šimůnek P, Holčapek M, Kašparová P: Synthesis and characterisation of a new amphotericin B-methoxypoly(etylene glycol)conjugate. Bioorg Med Chem Lett 2001; 11: 2833-2835. Go to original source...
    27. Vopršalová M: oral communication.
    28. ConoverChD, Zhao H, Longley CB, Shum KL, Greenwald RB: Utility of poly(ethylene glycol)conjugation to create prodrugs of amphotericin B. Bioconj Chem 2003; 14: 661-666. Go to original source... Go to PubMed...
    29. Ehrenfreund-Kleinman T, Azzam T, Falk R, Polacheck I, Golenser J, Domb AJ: Synthesis and characterization of novel water soluble amphotericin B-arabinogalactan conjugates. Adv Drug Delivery Rev 2003; 55: 217-250.
    30. Cybulska B, Kupczyk K, Szlinder-Richert J, Borowski E: Comparative in vitro studies on liposomal formulatioms of amphotericin B and its derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester (MFAME). Acta Biochim Pol 2002; 49: 66-75. Go to original source...

    Return to the content